What is MPS Pharmaa Ltd (531686) share price return in the past 10 years?

MPS Pharmaa Ltd share price has declined -11.6% annually (CAGR) over the past ten years.

What is the share price of MPS Pharmaa Ltd (531686)?

Company share prices are keep on changing according to the market conditions. The current trading price of MPS Pharmaa Ltd (531686) on 13-Apr-2026 16:59:59 at 16:59 is 1.73.

What is the P/E ratio of MPS Pharmaa?

The latest standalone P/E ratio of MPS Pharmaa as of 13-Apr-2026 is 0.00.

What is the P/B ratio of MPS Pharmaa Ltd (531686)?

The latest standalone P/B ratio of MPS Pharmaa Ltd (531686) as of 13-Apr-2026 is 7.88.

What is the 52-week high and low of MPS Pharmaa Ltd (531686)?

The 52-week high of MPS Pharmaa Ltd (531686) is Rs. 3.17 and the 52-week low is Rs. 1.57.

MPS Pharmaa Ltd (531686) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: MPS Pharmaa Ltd (531686)
Brand: MPS Pharmaa

MPS Pharmaa Ltd (531686) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

MPS Pharmaa Ltd (531686)

BSE: 531686 NSE:

Key Metrics

Market Cap

₹3 Cr.

P/E Ratio

0.00

Price to Book (P/B)

7.88

Price to Sales (P/S)

0.00

EV/EBITDA

-14.04

Return on Capital Employed (ROCE)

-9.70%

Current Price

₹1.7

Return on Equity (ROE)

-58.89%

Return on Assets (ROA)

-9.32%

Operating Profit Margin

Net Profit Margin

-INF%

Gross Profit Margin

Book Value per Share

₹0.2

Sales Growth (YoY)

NA%

Sales Growth (3 Years)

-100%

Operating Profit Growth (1 Year)

NA%

Operating Profit Growth (3 Years)

N/A%

Net Profit Growth (1 Year)

NA%

52-Week Low / High

₹2 / 3

Net Profit Growth (3 Years)

N/A%

Dividend Yield

0.00%

Promoter Holding

35.89%

Pledged shares (%)
of Promoter's holding (%)

16.04%

Check Before You Invest

Q.1 Revenue growth of MPS Pharmaa Ltd?

MPS Pharmaa Ltd revenue growth is 0% for FY-2025 , which is in line with its 5 year CAGR of 0% , indicating stable growth.

Q.1 Promoter shareholding and pledge status of MPS Pharmaa Ltd?

Promoters hold 35.89% of the MPS Pharmaa Ltd, with 16.04% of their stake pledged, indicating high pledge risk.

Q.1 Revenue growth of MPS Pharmaa Ltd vs industry peers?

MPS Pharmaa Ltd revenue CAGR is 0.00% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.

Q.1 Which industry/sub-sector does MPS Pharmaa Ltd belong to?

MPS Pharmaa Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of MPS Pharmaa Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -11.9% based on the current price.

DeciZen - make an informed investing decision on MPS Pharmaa

Based on:

Data

M-Cap below 100cr DeciZen not available

MPS Pharmaa stock performance

Key Ratios

Is MPS Pharmaa Ltd an attractive stock to invest in?

1. Is MPS Pharmaa Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that MPS Pharmaa Ltd is a below average quality company.

2. Is MPS Pharmaa Ltd undervalued or overvalued?

The key valuation ratios of MPS Pharmaa Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is MPS Pharmaa Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of MPS Pharmaa Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-4.2%	-33.9%	-5.9%	-7.8%	-8.1%	-36.9%	-9.6%	-11.2%	-9.1%	-9.7%	-
Value Creation Index ⓘ	-1.3	-3.4	-1.4	-1.6	-1.6	-3.6	-1.7	-1.8	-1.7	-1.7	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	1.4	2.8	4.1	0.8	0	0	0	0	0	0	0
Sales YoY Gr.	-	110.4%	44%	-79.7%	-100%	NA	NA	-100%	NA	NA	-
Adj EPS ⓘ	-0.6	-3.9	-0.5	-0.7	-0.6	-2.4	-0.1	-0.6	-0.4	-0.5	-0.5
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	9.9	6.1	5.6	5	4.4	2.1	2	1.5	1	0.6	0.2
Adj Net Profit ⓘ	-1.2	-7.4	-0.9	-1.3	-1.2	-4.5	-0.1	-1.1	-0.8	-0.9	-1
Cash Flow from Ops. ⓘ	1.3	0.4	-0.3	0.6	-0.5	-0.9	-4.3	-0.9	-0.6	-0.6	-
Debt/CF from Ops. ⓘ	5.3	17.9	-19.5	10.5	-12.8	-6.1	-1.3	-7.8	-11.5	-13.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-100%	NA	-100%	NA
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	-27.2%	-33.5%	-34.2%	-44.7%
Share Price	-11.6%	12.3%	-6.3%	-42.7%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-6.2	-48.3	-7.7	-12.3	-13	-73.7	-3.6	-31.8	-34.9	-58.9	-124.1
Op. Profit Mgn % ⓘ	-36.4	-242	-12.8	-86.8	-15362.1	0	-2079.4	0	0	0	NAN
Net Profit Mgn % ⓘ	-87.9	-259.8	-21.1	-150.5	-26692.7	0	-437.3	0	0	0	-INF
Debt to Equity ⓘ	0.4	0.6	0.6	0.7	0.8	1.4	1.5	2.4	3.7	6.9	-
Working Cap Days ⓘ	4,113	1,300	621	2,611	4,39,267	0	23,660	0	0	0	0
Cash Conv. Cycle ⓘ	3,209	1,017	413	1,651	2,62,890	0	9,803	0	0	0	0

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years -100.00%

Debt to equity has increased versus last 3 years average to 6.90

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	-0.5	-
TTM Sales (₹ Cr.)	0	-
BVPS (₹) ⓘ	0.2	-
Reserves (₹ Cr.) ⓘ	-19	-
P/BV ⓘ	7.88	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	1.57 / 3.17
All Time Low / High (₹)	0.32 / 53.25
Market Cap (₹ Cr.)	3.3
Equity (₹ Cr.)	19.1
Face Value (₹)	10
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

16.04

* Pledged shares as % of Promoter's holding (%)

Valuation of MPS Pharmaa - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	1.35	2.84	4.09	0.83	0	0	0.03	0	0	0
Operating Expenses ⓘ +	1.85	9.72	4.62	1.55	0.68	4.13	0.71	0.95	0.80	0.76
Manufacturing Costs	0.18	0.29	0.15	0.05	0.06	0.07	0.06	0.21	0.07	0.06
Material Costs	0.41	8.22	3.51	0.82	0	0	0.05	0.04	0	0
Employee Cost	0.78	0.79	0.65	0.49	0.45	0.40	0.42	0.49	0.53	0.52
Other Costs ⓘ	0.47	0.42	0.30	0.18	0.17	3.66	0.18	0.21	0.20	0.18
Operating Profit ⓘ	-0.49	-6.88	-0.53	-0.72	-0.67	-4.13	-0.67	-0.95	-0.80	-0.76
Operating Profit Margin (%)	-36.4%	-242.0%	-12.8%	-86.8%	-15,422.5%	-	-2,079.4%	-	-	-
Other Income ⓘ +	0	0.03	0.06	0.02	0.01	0.20	0.26	0.02	0.09	0.05
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.08	0	0	0	0	0	0	0	0	0
Depreciation ⓘ	0.62	0.59	0.59	0.59	0.57	0.56	0.51	0.15	0.15	0.15
Profit Before Tax ⓘ	-1.20	-7.44	-1.06	-1.29	-1.24	-4.49	-0.93	-1.07	-0.85	-0.86
Tax ⓘ	-0.01	-0.06	-0.19	-0.05	-0.07	-0.08	-0.79	-0.02	-0.02	0.03
Profit After Tax	-1.19	-7.39	-0.87	-1.25	-1.17	-4.42	-0.14	-1.05	-0.83	-0.90
PAT Margin (%)	-87.9%	-259.0%	-21.1%	-150.0%	-26,735.0%	-	-437.0%	-	-	-
Adjusted EPS (₹)	-0.6	-3.9	-0.5	-0.7	-0.6	-2.3	-0.1	-0.6	-0.4	-0.5
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	18.98	11.61	10.76	9.53	8.36	3.95	3.83	2.79	1.97	1.08
Share Capital ⓘ	19.11	19.11	19.11	19.11	19.11	19.11	19.11	19.11	19.11	19.11
Reserves ⓘ	-0.13	-7.50	-8.35	-9.58	-10.75	-15.16	-15.29	-16.32	-17.14	-18.03
Debt +	3.87	2.90	2.90	2.51	2.54	1.93	5.81	6.76	7.27	7.46
Long Term Debt	0.98	0	0	0	0	0	0	0	0	0
Short Term Debt	2.90	2.90	2.90	2.51	2.54	1.93	5.81	6.76	7.27	7.46
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0.64	0.36	0.14	0.16	0.15	0.09	0.12	0.20	0.20	0.20
Others Liabilities ⓘ	5.08	6.06	5.36	5.36	5.37	5.33	0.40	0.43	0.49	0.59
Total Liabilities ⓘ	28.57	20.93	19.15	17.56	16.41	11.30	10.16	10.19	9.94	9.33
Fixed Assets
Net Fixed Assets ⓘ +	7.64	7.06	6.47	5.88	5.26	4.68	4.17	4.14	4.01	3.83
Gross Block	16.15	16.16	16.16	16.16	16.05	15.71	15.72	15.84	15.86	15.17
Accumulated Depreciation	8.51	9.10	9.69	10.28	10.79	11.04	11.55	11.70	11.84	11.33
CWIP ⓘ	6.15	5.51	5.21	5.43	5.02	3.90	3.42	3.40	3.26	2.91
Investments ⓘ	0.92	0.92	0.92	0.92	0.92	0.54	0.54	0.54	0.54	0.54
Inventories	7.53	1.13	0.57	0.57	0.57	0.57	0.55	0.50	0.50	0.50
Trade Receivables	4.27	4.14	3.86	2.61	2.53	0.59	0.03	0.03	0.02	0.01
Cash Equivalents	0.03	0.06	0.02	0.02	0.01	0.01	0.01	0.01	0.01	0
Others Assets ⓘ	2.03	2.11	2.11	2.12	2.09	1.02	1.43	1.57	1.60	1.53
Total Assets ⓘ	28.57	20.93	19.15	17.56	16.41	11.30	10.16	10.19	9.94	9.33

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	1.25	0.37	-0.34	0.60	-0.49	-0.93	-4.34	-0.87	-0.63	-0.57
PBT ⓘ	-1.20	-7.43	-1.06	-1.29	-1.24	-4.49	-0.56	-1.05	-0.84	-0.88
Adjustment ⓘ	0.74	0.61	0.62	0.60	0.59	0.58	0.51	0.15	0.15	0.15
Changes in Working Capital ⓘ	1.89	7.2	0.1	1.29	0.15	2.98	-4.3	0.04	0.06	0.17
Tax Paid ⓘ	-0.18	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-0.05	0.63	0.30	-0.21	0.46	1.54	0.46	-0.10	0.12	0.38
Capex	-0.05	0.63	0.30	-0.22	0.05	0.03	-0.01	-0.12	-0.02	0.03
Net Investments	0	0	0	0	0	0.39	0	0	0	0
Others ⓘ	0	0	0	0.01	0.41	1.13	0.47	0.02	0.14	0.35
Cash Flow From Financing Activity ⓘ +	-1.19	-0.98	-0	-0.39	0.03	-0.61	3.88	0.96	0.51	0.18
Net Proceeds from Shares ⓘ	0.97	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-0.98	-0.98	0	-0.39	0.03	-0.61	3.88	0.96	0.51	0.18
Interest Paid ⓘ	-0.08	-0	-0	-0	-0	-0	-0	-0	-0	-0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-1.10	0	0	0	0	-0	0	-0	0	-0
Net Cash Flow ⓘ	0.01	0.02	-0.04	0	-0	0	0	-0.01	-0	-0

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-6.79	-48.3	-7.74	-12.28	-13.04	-71.73	-3.64	-31.75	-34.92	-58.89
ROCE (%)	-4.23	-33.9	-5.91	-7.76	-8.08	-36.9	-9.64	-11.15	-9.06	-9.7
Asset Turnover Ratio	0.04	0.12	0.2	0.05	0	0	0	0	0	0
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	1,592	515	357	1,426	0	0	3,546	0	0	0
Inventory Days	1,982	531	76	252	0	0	6,294	0	0	0
Payable Days	1,758	22	26	66	0	0	770	1,304	0	0

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

MPS Pharmaa Ltd FAQs

The current trading price of MPS Pharmaa on 13-Apr-2026 16:59 is ₹1.73.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2026 the market cap of MPS Pharmaa stood at ₹3.31 Cr

The latest P/E ratio of MPS Pharmaa as of 12-Apr-2026 is 0.00.

The latest P/B ratio of MPS Pharmaa as of 12-Apr-2026 is 7.88.

The 52-week high of MPS Pharmaa is ₹3.17 and the 52-week low is ₹1.57.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of MPS Pharmaa is ₹0.00 ( Cr.) .

About MPS Pharmaa Ltd

Advik Laboratories has been set up by V K Jain, a qualified production chemist with over 20 years experience in pharmaceutical products.

Advik Laboratories was established in the 1994. It is WHO-GMP certified company that has been set up from the ground level with the avowed objective of achieving USFDA standards of quality.

The company has a technical collaboration with PFC Pharma Focus of Switzerland. It enjoys leadership status at various fronts such as high product quality, a growing range of products, state of the art manufacturing process, competitive pricing and customer service. In addition the company exports a wide range of drugs to the Middle East, South America and Africa.

The product range includes ethical, generic drugs and over the counter drugs (OTC) in various formulations.

With over 60,000 square feet of built-up area, ample developed open space around it, a state-of-the-art manufacturing facility, the ground floor has provisions for the production and in-process control section for the manufacturing of steroidal & non-steroidal formulations, change room for gents & ladies and stores for raw & packing materials. The first floor has provision for the production and in-process control section for the manufacturing of ampicillin and non-ampicillin capsules and dry syrup preparations. The second floor has provision for quality control and about 12000 sq ft area is presently being reserved for the manufacture of injectables & ointments in the second phase.

Advik Laboratories provides pharmaceutical formulations that match the international standards of quality. The facility manufactures a wide range of pharmaceuticals formulations in tablets, capsules and dry syrups.

Products - Under Ethical products, the company manufactures Wibatol, Wibatol-O, Robial, Twosum, Majispa, Arfa Gel, Stibomin and Chewfe-C.

Under generic products, the company manufactures drugs catering segment such as antibacterials, antiallergics, antifungals, analgesic, antipyretic and anti-inflammatory, anti-hypertensives, anthelminthics, anti-malarials, corticosteroids, erectile dysfunction, gastrointestinal agents and sedatives.

Award - Advik Laboratories has received the prestigious Udyog Patra Award from the Government of India in 1999.

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

MPS Pharmaa Ltd (531686) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

MPS Pharmaa Share Price